ARCHIVES

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

This article is from The Cancer Letter archive.

Vol. 17 No. 32 | August 9, 1991

Download PDF Visit The Full Archive

Related Articles

Patient Advocacy: MBCC Conference Issues Statement On Equal Status On Advocates

April 4, 1997

Drugs and Targets: FDA extends Lymphoseek label to include mapping in solid tumors

October 31, 2014

NCI Advisory Group, Other Cancer Meetings

May 29, 1987

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

April 25, 2014

Funding opportunities listed.

May 7, 2004

NCI-supported meeting included tobacco industry representatives in dialogue on ethics.

October 29, 2004